On Friday, trade beat reporters for multiple media outlets reported that the Biden administration was considering a new "Section 301" unfair trade investigation of China.
This one reportedly would examine China's industrial subsidies. 1/
The Biden administration is targeting Beijing’s widespread use of industrial subsidies that give its companies an edge over foreign rivals
Yes, Section 301 is the US trade law that Trump used to legally implement trade war tariffs that still cover $335bn of imports from China, have led to Chinese retaliation hitting 58% of US exports to China. piie.com/research/piie-… 5/
Trump's Section 301 investigation focused on China's unfair intellectual property rights practices, including forced technology transfer (FTT), corporate espionage, and other forms of IP theft hurting American companies. 6/
More generally, Section 301 is the law under which the US government conducts unfair trade investigations. The law does not say the outcome must be more tariffs. Eg, Section 301 was used to investigate Europe's digital services taxes, where tariffs are not being imposed. 7/
At this stage it is premature to speculate that Biden is doing this simply to impose more tariffs on China. It could turn out that way. But it could turn out many other ways too.
Why is Biden doing THIS investigation? 8/
China's economic system of direct subsidies, state-owned enterprises, and combination of OTHER policies that replicate the effect of economic subsidies are a challenge for the United States as well as the EU, Japan, and other countries in the trading system. 9/
Trump's unilateral trade war approach of tariffs did not make any progress. As @J_A_Hillman and I wrote in October 2019, Trump’s Phase One “Truce” did NOTHING to tackle the China subsidy problem.
This was unsurprising.
Confronting China's subsidies is not something the US can pull off alone for simple cost/benefit reasons. Because the US would not capture the full "benefit" of addressing China's subsidies - some would spillover to EU, Japan, etc - the US alone won't invest sufficiently. 11/
Again, the Section 301 investigation is only the first step.
Note: Coincidentally, US and EU also announced last week dates for the first ministerial meeting of the EU-US Trade and Technology Council, where some of this may be discussed
Here is a paper that SUMMARIZES -- all in one place -- the key US-China trade war actions and Phase One agreement during the Trump administration. (All the stuff that took place January 20, 2017 - January 20, 2021.) piie.com/publications/w… 13/
US-China trade welcome back!
Here is the latest monthly update to the status of China's purchase commitments under the Phase One agreement. piie.com/research/piie-… 14/
In my 10 years as a professor, I struggled to find material on contemporary policy issues for my SYLLABUS.
The speed & novelty of today's policy changes impacting trade make the challenge **YOU** face even greater.
Here is a small attempt to help... 1/🧵
Here are four (IV) papers. Each...
• contains a positive explanation of what happened
• leans heavily (and makes available) data
• admittedly raises more questions than it answers
(though, since the policy issues remain unresolved, perhaps that is a feature, not a bug...) 2/
I. COVID-19 VACCINES: How dozens of companies at nearly 100 geographically distributed sites came together to form supply chains to manufacture billions of doses from Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, and CureVac... 3/
CureVac's COVID-19 mRNA vaccine may not be salvageable. However, the company's brand new manufacturing supply chain - capable of delivering 1 billion doses - should be. But doing so requires creative industry / policymaker collaboration.
On April 15, CureVac had announced its supply chain was on track to manufacture 300 million doses of its mRNA vaccine by the end of 2021 and another 1 billion doses in 2022, upon regulatory approval.
How in the world did we end up with billions of doses of COVID-19 vaccines manufactured by Pfizer/ BioNTech, Moderna, AstraZeneca, and Johnson & Johnson?
Roughly 4 billion doses of COVID-19 vaccines have now been administered worldwide. Most required a two-dose regimen—if that trajectory continued, close to 14 billion shots would be needed to inoculate the global population. 2/
Getting a new vaccine from beginning to end — from concept to delivering shots into the public’s arms — requires five steps associated with five, largely separable, sets of fixed costs. 3/
COVID-19 meant devastating shortages of personal protective equipment (PPE), like masks, gowns and gloves. What happened to trade, the unprecedented trade and industrial policy to emerge, as well as lessons learned for future preparedness.
Chip shortage! The Biden administration and US allies have now committed to work together on semiconductor policy. That will prove hard. Why it's needed, and where to start.
The chip shortage facing automakers heightened the issue's seriousness. But the supply of semiconductors was at risk long before the pandemic, and COVID-19 is only partly to blame for today’s problems.
One of the biggest culprits was a sudden shift in US trade policy... 2/
Trump imposed 25% trade war tariffs on semiconductors beginning in July 2018. The US now imports **half as many** semiconductors from China as it did pre-trade war. (That's billions of fewer chips).
Those missing chips have NOT been replaced by imports from elsewhere... 3/